Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9730226 | 0.81 | PTGS2 (0.43) | PTGS2GABRA5IDO1TDO2LMNA | |
| SCHEMBL12530467 | 0.77 | PTGS2 (0.60) | PTGS2IDO1TDO2LMNADCTPP1 | |
| SCHEMBL13754460 | 0.77 | PTGS2 (0.56) | PTGS2IDO1TDO2DCTPP1ALDH1A1 | |
| SCHEMBL2687662 | 0.74 | KCNN4 (0.49) | KMT2A | |
| SCHEMBL13754468 | 0.72 | PTGS2 (0.55) | PTGS2GABRA5LMNADCTPP1TP53 | |
| SCHEMBL9894965 | 0.72 | PTGS2 (0.63) | PTGS2GABRA5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2684032 | 0.71 | GABRA5 (0.74) | PTGS2GABRA5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2684034 | 0.71 | GABRA5 (0.74) | PTGS2GABRA5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2683661 | 0.70 | PTGS2 (0.49) | PTGS2GABRA5LMNADCTPP1ALDH1A1 | |
| SCHEMBL21834124 | 0.70 | GABRA5 (0.46) | PTGS2GABRA5IDO1TDO2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| CN-103221402-A | Triazole derivatives and their use for neurological disorders | HOFFMANN LA ROCHE | 2013-07-24 | — | — | CN | disclosed |
| CN-103189370-A | Triazole derivatives as ligands for GABA receptors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | disclosed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2009105746-A2 | TRIAZOLES AND PROCESSES FOR PRODUCING THE SAME | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-08-27 | — | — | WO | disclosed |
| US-5081136-A | 1,2,3-TRIAZOLE COMPOUNDS ACTIVE AS INHIBITORS OF THE ENZYME HMG-COA REDUCTASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAMBON GROUP S.P.A. (IT) | 1992-01-14 | — | — | US | disclosed |
| EP-0433842-A2 | 1,2,3-Triazole derivatives active as inhibitors of the enzyme HMG-COA reductase and pharmaceutical compositions containing them | ZAMBON GROUP S.p.A. (IT) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | PTGS2 3000/4885GABRA5 1/4885IDO1 1133/4885 |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | PTGS2 2516/4885GABRA5 1/4885IDO1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.